Ads
related to: scholarly articles on hiv aids treatment- Patient Assistance Info
Discover If You Are Eligible To
Save On An HIV-1 Treatment Option.
- Download Patient Brochure
Find Resources With Important Info
About Treatment And Switching.
- HIV Real Patient Stories
Watch The Stories Of People Who
Share Their Treatment Experiences.
- HIV Treatment FAQs
Find Answers To Frequently Asked
Questions About HIV And Medication.
- Sign Up For More Info
Learn About An HIV Treatment Option
Sign Up To Receive Information.
- Learn How Treatment Works
Visit The Patient Website To Learn
How An HIV-1 Treatment Works.
- Patient Assistance Info
Search results
Results From The WOW.Com Content Network
Scanning electron micrograph of HIV-1, colored green, budding from a cultured lymphocyte Diagram of HIV. HIV/AIDS research includes all medical research that attempts to prevent, treat, or cure HIV/AIDS, as well as fundamental research about the nature of HIV as an infectious agent and AIDS as the disease caused by HIV.
The successful treatment and management of HIV/AIDS is affected by a plethora of factors which ranges from successfully taking prescribed medications, preventing opportunistic infection, and food access etc. Food insecurity is a condition in which households lack access to adequate food because of limited money or other resources.
HIV/AIDS: Research and Palliative Care is a peer-reviewed medical journal covering HIV and its treatment. The journal was established in 2009 and is published by Dove Medical Press. It is abstracted and indexed in PubMed, EMBASE, EmCare, and Scopus.
The diminished rate of new HIV infections brought about by these strategies are marked progress towards UNAIDS' 90-90-90 and 95-95-95 target to eliminate HIV/AIDS as a public health crisis by 2030. [8] However, key populations in countries in Africa, Asia, and the Middle East may still have lower access to treatment. [9]
HIV-1 protease is one of the best known aspartic proteases, and an attractive target for the treatment of AIDS. [9] After the discovery of HIV protease it only took 10 years for its first inhibitor to reach the market. [10] The first reports of highly selective antagonists against the HIV protease were revealed in 1987.
Rilpivirine, sold under the brand names Edurant and Rekambys, is a medication, developed by Tibotec, used for the treatment of HIV/AIDS. [5] [6] It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs such as efavirenz.
Ads
related to: scholarly articles on hiv aids treatment